An exclusive license to develop and sell flu vaccines using it’s technology has just been given to pharmaceutical company LG Life Sciences Ltd by Novavax. Inc., for use in South Korea.
LG also receives a non-exclusive license to make and sell flu vaccines in certain emerging markets. LG will be responsible for funding development of the vaccines in South Korea and other countries, while Novavax will receive upfront and milestone payments, along with double-digit royalty rate payments on future commercial sales. Read the complete article
Hear John Trizzino of Novavax discuss collaborations and co-development between start-up biotech and big pharma in this video from the World Vaccine Congress Washington.
Collaborations and co-development between start-up biotech and big pharma:
â€¢ Market opportunities and their impact on partnerships
â€¢ What do companies look for within market trends?
Visit our Website: http://www.terrapinn.com/2013/world-vaccine-congress-washington/index.stm
Read our blog: http://blogs.terrapinn.com/vaccinenation/
Follow us on Twitter: @vaccinenation
Join our Linkedin group: http://www.linkedin.com/groups/Vaccine-Nation-1351197